In a filing, Iovance Biotherapeutics Inc revealed its Director Rothbaum Wayne P. acquired Company’s shares for reported $45.75 million on Feb 20 ’24. In the deal valued at $9.15 per share,5,000,000 shares were bought. As a result of this transaction, Rothbaum Wayne P. now holds 28,067,333 shares worth roughly $317.44 million.
Then, MCPEAK MERRILL A bought 250,000 shares, generating $2,287,500 in total proceeds. Upon buying the shares at $9.15, the Director now owns 320,150 shares.
Before that, Dukes Iain D. bought 32,000 shares. Iovance Biotherapeutics Inc shares valued at $292,800 were divested by the Director at a price of $9.15 per share. As a result of the transaction, Dukes Iain D. now holds 54,000 shares, worth roughly $0.61 million.
Goldman initiated its Iovance Biotherapeutics Inc [IOVA] rating to a Buy in a research note published on November 20, 2023; the price target was $12. A number of analysts have revised their coverage, including Barclays’s analysts, who remained covering the stock and in mid September has reiterated a ‘”an Overweight”‘ rating for it. Wells Fargo also remained covering IOVA and has increased its forecast on May 30, 2023 with a “an Overweight” recommendation from previously “an Equal weight” rating.
Price Performance Review of IOVA
On Friday, Iovance Biotherapeutics Inc [NASDAQ:IOVA] saw its stock fall -3.50% to $11.31. Over the last five days, the stock has lost -8.50%. Iovance Biotherapeutics Inc shares have risen nearly 39.11% since the year began. Nevertheless, the stocks have risen 93.33% over the past one year. While a 52-week high of $18.33 was reached on 02/28/24, a 52-week low of $3.21 was recorded on 01/29/24. SMA at 50 days reached $13.76, while 200 days put it at $8.14. A total of 5.26 million shares were traded, compared to the trading of 3.7 million shares in the previous session.
Levels Of Support And Resistance For IOVA Stock
The 24-hour chart illustrates a support level at 10.98, which if violated will result in even more drops to 10.66. On the upside, there is a resistance level at 11.66. A further resistance level may holdings at 12.02. The Relative Strength Index (RSI) on the 14-day chart is 33.26, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.10, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 90.62%. Stochastics %K at 8.12% indicates the stock is a buying.
